Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trial in children and adolescents with primary malignant liver cancer
2024-514635-26-00Phase 3Authorised
- Sponsor
- Medical University of Gdańsk
- Start
- Nov 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of sodium thiosulfate, cisplatin, carboplatin, sorafenib, irinotecan and 6 more in hepatoblastoma, hepatocellular carcinoma (HCC) and liver cancer, sponsored by Medical University of Gdańsk. Primary endpoints: Event-free survival, Overall survival and 6 more. Planned start Nov 2024; status: authorised.
02
Drugs
sodium thiosulfatecisplatincarboplatinsorafenibirinotecan
03
Conditions
hepatoblastomahepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on 2024-514635-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514635-26-00.